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Background: Lymph node status is not part of the staging system for cervical cancer, but provides important
information for prognosis and treatment. We investigated whether lymph node status can be predicted with
proteomic profiling.
Material & methods: Serum samples of 60 cervical cancer patients (FIGO I/II) were obtained before primary
treatment. Samples were run through a HPLC depletion column, eliminating the 14 most abundant proteins
ubiquitously present in serum. Unbound fractions were concentrated with spin filters. Fractions were spotted onto
CM10 and IMAC30 surfaces and analyzed with surface-enhanced laser desorption time of flight (SELDI-TOF) mass
spectrometry (MS). Unsupervised peak detection and peak clustering was performed using MASDA software.
Leave-one-out (LOO) validation for weighted Least Squares Support Vector Machines (LSSVM) was used for
prediction of lymph node involvement. Other outcomes were histological type, lymphvascular space involvement
(LVSI) and recurrent disease.
Results: LSSVM models were able to determine LN status with a LOO area under the receiver operating
characteristics curve (AUC) of 0.95, based on peaks with m/z values 2,698.9, 3,953.2, and 15,254.8. Furthermore, we
were able to predict LVSI (AUC 0.81), to predict recurrence (AUC 0.92), and to differentiate between squamous
carcinomas and adenocarcinomas (AUC 0.88), between squamous and adenosquamous carcinomas (AUC 0.85), and
between adenocarcinomas and adenosquamous carcinomas (AUC 0.94).
Conclusions: Potential markers related with lymph node involvement were detected, and protein/peptide profiling
support differentiation between various subtypes of cervical cancer. However, identification of the potential
biomarkers was hampered by the technical limitations of SELDI-TOF MS.
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reproduction in any medium, provided the oraccounting for nearly one in ten (9%) of all cancers diag-
nosed in women. The developing countries carry the
biggest burden of cervical cancer, with more than
450,000 cases being diagnosed in 2008 [1].
Lymph node (LN) status is not part of the staging sys-
tem of the International Federation of Gynecology and
Obstetrics (FIGO) for cervical cancer [2], but it provides
important information for prognosis and treatment, in
particular in early stage cervical cancer [3,4]. The inci-
dence of pelvic LN metastases varies from 0–2% in
FIGO stage IA, 17–24% in FIGO stage IB1, 17–50% in
FIGO stage IB2, and 10–50% in FIGO stage IIa [4-10].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment of choice is either surgical, including radical hys-
terectomy and pelvic LN dissection, or chemoradiation.
Combining both treatments leads to a higher morbidity,
such as lymph edema and urological complications [11].
Specifically for patients with lymph node metastases,
chemoradiation is the treatment of choice since it
reduces local and distant recurrences [12]. Preoperative
diagnostic modalities such as CT scan and MRI have a
good specificity, but a low sensitivity [13,14]. This
explains why a certain number of patients, in whom the
diagnosis of positive LN is only made after pathological
examination, still receive a combined treatment of sur-
gery and pelvic irradiation.
Various proteomics techniques have been used to de-
tect new biomarkers in gynaecological cancers with vari-
able degrees of success [15]. Over the last decade,
surface-enhanced laser desorption time of flight (SELDI-
TOF) mass spectrometry (MS) has been a popular pro-
teomics technique due to its ease of use and high
throughput. Several studies have published comparative
studies on new diagnostic proteins [15].
We investigated whether we could improve the predic-
tion of LN involvement with SELDI-TOF MS proteomic
profiling.Results
Patients
Patient and tumour characteristics are represented in
Table 1. Twelve patients were diagnosed with positive
LNs. The remainder of the patients had a complete lym-
phadenectomy performed, but no positive lymph nodes
were diagnosed. Both groups were well balanced for age,
FIGO stage, histological subtype, number of removed
LNs, incidence of LVSI, duration of follow-up and inci-
dence of recurrence. LVSI was—as expected—associated
with LN status.Unsupervised peak detection
In total 597 different peaks were detected in our panel
of 60 samples: 284 peaks on CM10 and 313 on IMAC30.
In Table 2 the number of peaks that was differentially
expressed according to LN status, histological subtype,
LVSI and recurrence of disease are shown. In general,
the number of differentially expressed peaks was higher
in the low mass range, except for the difference between
squamous carcinomas and adenocarcinomas. The total
number of differentially expressed peaks ranged from 11
to 37, depending on the comparison which was made. A
complete list of the m/z values of the differentially
expressed peaks with corresponding p-values is provided
in Additional file 1.LOO internal validation for weighted LSSVM
The AUC values obtained by LOO internal validation
with the optimal median and mean number of peaks
across all LOO iterations are represented in Table 3. For
the prediction of LN status an AUC value of 0.95 was
obtained (Figure 1). Three peaks were repeatedly
selected in the LOO iterations: m/z values 2,698.9,
3,953.2, and 15,254.8 from the IMAC low mass, CM10
low mass, and IMAC high mass spectra, respectively
(Table 4).
LVSI was more difficult to predict. Although a median
number of one peak was sufficient, the LOO AUC
reached only a value of 0.81. A median number of 1
peak was needed to construct a model that was able to
differentiate squamous carcinomas with adenocarcin-
omas (AUC 0.88), 4 peaks to differentiate between squa-
mous and adenosquamous carcinomas (AUC 0.85), 1
peak to differentiate between adenocarcinomas and ade-
nosquamous carcinomas (AUC 0.94), and 3 peaks to
predict recurrence (AUC 0.92). The most frequently
selected peaks for the different comparisons are repre-
sented in Table 4.Discussion
This study investigated whether we could improve the
prediction of LN involvement with proteomic profiling.
We used a combination of HPLC immunodepletion with
SELDI-TOF MS to detect proteins that predict LN in-
volvement. Using LSSVM models we were able to pre-
dict lymph node involvement with an AUC of 0.95.
These findings suggest that serum biomarkers could
help us identifying patients with LN metastases. Other
outcomes, such as histological type (AUC= 0.85–0.94),
lymph vascular space involvement (AUC= 0.81) and re-
currence (AUC= 0.92), were also successful, however the
number of patients in some of the subgroups was lim-
ited (e.g. adenosquamous subtype (n = 2)) making the
results less reliable.
The majority of serum proteins are high-abundance pro-
teins, accounting for almost 99% of the total protein mass
[16]. Most of these proteins are true serum or plasma pro-
teins that carry out their functions in the circulation, rather
than proteins or peptides that leak into the blood (e.g.
tumor tissue proteins) [16]. Removing the high abundant
proteins facilitates the discovery and identification of low-
abundance proteins that may be biomarkers [17]. The
MARS-14 immunodepletion column used in the present
study removes 95–99% of the 14 most abundant proteins
from serum, thereby increasing the likeliness of finding pos-
sible biomarkers [18,19]. This technique has proven to be
highly reproducible [19]. However, due to protein–protein
or protein–antibody interactions also non-targeted proteins
are being removed [19,20] which could hamper the
Table 1 Patient and tumour characteristics





Age in years Mean (95%CI) 45.8 (38.5–53.0) 46.7 (43.3–50.0) T-test 0.732
FIGO stage
Ia2 n (%) 0 (0.0) 2 (4.2) χ2 0.134
Ib1 n (%) 6 (50.0) 37 (77.1)
Ib2 n (%) 2 (16.7) 2 (4.2)
IIa n (%) 4 (33.3) 7 (14.6)
Histological subtype
Squamous cell carcinoma n (%) 11 (91.7) 29 (60.4) χ2 0.119
Adenocarcinoma n (%) 1 (8.3) 17 (35.4)
Adenosquamous carcinoma n (%) 0 (0.0) 2 (4.2)
Lymph nodes
Number of positive LN Median (min-max) 1 (1–7) 0 (0–0) Mann–Whitney <0.001
Number of removed LN Median (min-max) 28 (4–50) 34 (18–89) Mann–Whitney 0.241
LVSI
Positive n (%) 10 (83.3) 16 (33.3) χ2 0.005
Negative n (%) 2 (16.7) 32 (66.7)
Follow-up
Follow-up (in months) Mean (95%CI) 61.8 (42.0–81.5) 61.7 (49.0–66.5) T-test 0.997
Recurrence
Recurrence n (%) 3 (25.0) 7 (14.6) χ2 0.665
No recurrence n (%) 9 (75.0) 41 (85.4)
Abbreviations: LN = lymph node; FIGO = International Federation of Gynecology and Obstetrics; LVSI = lymphvascular space involvement.
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tion that the detection of medium abundance proteins
improves, but not the detection of the very low abundance
proteins (<10 ng/mL) [18]. This is the range in which some
of the currently known biomarkers are found (e.g. CEA)
[16]. Another problem with immunodepletion in combin-
ation with SELDI-TOF MS is that both systems, the HPLC
and SELDI-TOF MS are not in-line as other LC-MS techni-
ques. The additional sample handling introduces additional
experimental variables, such as additional freezing/thawing
cycles, and manually handling of the samples.
Upon establishing the biomarker profiles for lymph node
involvement in cervical cancers, it became interesting to
identify the proteins behind the differentially expressed
peaks. For the 15,254.8 peak detected on the IMAC30 chip,
an approach was developed using immunodepletion and
SDS-PAGE gel electrophoresis as initial separation steps.
Unfortunately, due to the apparently very low concentra-
tion of this protein in serum, no Coomassie Blue band
could be detected at the level of 15–16 kDa. For the two
lower masses (2,698.9 and 3,953.2) an attempt was under-
taken for direct identification from the corresponding
SELDI target plate. This involved the use of a special SELDI
Chip target adapter (Bruker Daltonics, Bremen, Germany)to analyze the spots with a matrix-assisted laser desorption/
ionization (MALDI)-TOF/TOF MS (Ultraflex 2, Bruker
Daltonics, Bremen, Germany). Indeed, the TOF/TOF MS
can induce fragmentation of selected masses, which is es-
sential for their subsequent identification. However, SELDI-
TOF MS is known for having a poor mass accuracy or re-
producibility [21]. This made it difficult to determine which
peak in the 2,650–2,750 and the 3,900–4,000 Da range on
MALDI-TOF MS/MS was responsible for the 2,698.9 and
3,953.2 peaks on SELDI-TOF. Moreover, collision induced
dissociation (CID) of high mass peaks (>3 kDa) is difficult
in currently available MALDI TOF/TOF MS instruments,
yielding no or incomplete fragments from this masses. Al-
ternatively, an off-line sample preparation was explored to
allow analysis of larger volumes of samples using a MALDI
target plate. In this project, SELDI-TOF MS on-chip chro-
matographic surfaces are used to select proteins with either
cationic or metal affinity properties. This gives two advan-
tages to SELDI-TOF MS: (1) the chromatographic surface
acts as an additional fractionation step, selecting only a sub-
set of proteins that will be analyzed (enrichment), and (2)
the proteins get separated from salts and other sample con-
taminants by subsequent on-spot washing with appropriate
buffer solutions. As in MALDI MS analysis, on-chip
Table 2 The total number of identified peaks and the number of peaks that was significantly differentially expressed










Total number of peaks 175 109 172 141 597
Lymph node status
Negative vs Positive 2 0 5 5 12
Histological subtype
Squamous ca. vs Adenoca. 8 15 3 5 31
Squamous ca. vs Adenosquamous ca. 4 2 4 1 11
Adenoca. vs Adenosquamous ca. 3 0 18 0 21
LVSI
Negative vs Positive 18 0 14 5 37
Recurrence
Negative vs Positive 4 0 7 3 14
Abbreviations: CM10 = weak cation exchanger array; IMAC = immobilized metal affinity capture array; ca. = carcinoma; LVSI = lymph vascular space involvement.
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must be applied before the sample is put on the target to
reduce noise and ion suppression. In our identification
experiments we applied an additional desalting step by
using revered phase chromatography, either by HPLC, or
by C4 or C18 Zip-Tip. These additional steps introduced
additional experimental variables making it even more un-
certain to identify the correct protein. Taken together, the
additional sample preparations resulted in sample loss as
well as introducing qualitative and quantitative variances,
without leading to the required identification.
When looking at the literature on SELDI-TOF experi-
ments, it can be noticed that in only a minority of
papers an identification was performed. Most of the
papers mention that identification and validation of theTable 3 AUC obtained by leave-one-out internal validation (L
per iteration
LOO AUC (SE) Sensitivity
Lymph node status
Negative vs Positive 0.95 (0.03) 73.9
Histological subtype
Squamous ca. vs adenoca. 0.88 (0.05) 88.2
Squamous ca. vs adsq ca. 0.85 (0.06) 84.6
Adenoca. vs adsq ca. 0.94 (0.06) 94.1
LVSI
Negative vs Positive 0.81 (0.06) 78.1
Recurrence
Negative vs Positive 0.92 (0.04) 79.2
Abbreviations: SE = standard error; SD = standard deviation; ca. = carcinoma; Adsqnewly discovered biomarkers is ongoing. However,
follow-up papers on the identified proteins, or validation
studies are rarely published. For example, SELDI-TOF
MS was used to differentiate cervical cancer and normal
cervix tissue in the study by Wong et al. [22]. The
authors were able to discover a discriminatory peak pro-
file with a sensitivity of 87% and a specificity of 100%.
To the best of our knowledge there was no follow-up
study published in which these results were validated or
the proteins identified. Another example is the study by
Lin et al. [23] in which plasma proteomic profiling with
SELDI-TOF MS was used to differentiate in situ carcin-
oma and invasive carcinoma of the cervix. Although a
very high sensitivity and specificity was found with a
limited amount of differentially expressed peaks, thereOO) with the optimal median and mean number of peaks
Specificity Median number






91.7 1 1 (0)
59.0 1 1 (0)
100 4 3.8 (0.9)
100 1 0.9 (0.3)
73.1 1 1 (0)
90.0 3 3 (0)



















AUC = 0.947 
   SE = 0.030
0
0
Figure 1 Receiver operating characteristics (ROC) curve for the prediction of lymph node status. Abbreviations: AUC: area under the
curve, SE = standard error.
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is not only the case for biomarker discovery studies for
gynecological cancers [15], but also for various other
types of cancer [24,25]. This questions the utility/advan-
tage of the using a SELDI-TOF MS approach. Over the
last decade the field of mass spectrometry has evolved
and expanded with new techniques: high-definition MS
equipment and new software enables scientists to detect
proteins up to the femtogram level. Future developments
include tandem expansions with multiple connections to
HPLC equipment. In-depth analyses of fluid or tissue
specimens seems now possible. There is a place for a
global proteomics approach, but this should be an in-
depth proteomic profiling with high levels of fraction-
ation, separation and identification.Conclusions
In conclusion, the SELDI TOF MS approach has allowed
to discover a set of proteomic profiles (revealing poten-
tial biomarkers) that could help us in the diagnosis of
LN metastases. However, the proteins/peptides con-
cerned were not identified due to technical limitations of
the SELDI-TOF MS technique.Material and methods
Patients
Serum samples of 60 cervical cancer patients were
obtained before primary surgery. All patients were diag-
nosed with FIGO stage I or II cervical cancer. Prior to en-
rolment in the study, all patients were required to givefully informed consent. The protocol was approved by the
Local Ethics Committee (reference: 3M040097/ML2524).Depletion
For each of the 60 serum samples, immunodepletion
was performed using a high capacity 4.6 × 100 mm mul-
tiple affinity removal system (MARS) column (Agilent
Technologies, Diegem, Belgium) in an Agilent 1200 high
pressure liquid chromatography (HPLC) system (Agilent
Technologies, Diegem, Belgium). This column elimi-
nates the 14 most abundant proteins ubiquitously
present in serum: albumin, alpha1-acid glycoprotein,
alpha2-macroglobulin, antitrypsin, apolipoprotein AI,
apolipoprotein AII, complement C3, fibrinogen, hapto-
globin, IgA, IgG, IgM, transferrin, and transthyretin. In
brief, the serum samples were diluted four-fold with Buf-
fer A (Agilent Technologies, Diegem, Belgium), filtered
through a 0.22 mm spin filter and 100 μl of the diluted
serum was injected into the column in 100% Buffer A at
a flow rate of 0.125 mL/min. After collection of the
flow-through (i.e. depleted fraction) for 5.5 min, the col-
umn was washed and the bound (high abundance) pro-
teins were eluted with 100% Buffer B (Agilent
Technologies, Diegem, Belgium) at a flow rate of 1 mL/min
for 2.5 min. The column was re-equilibrated using
100% Buffer A. Protein elution was monitored at a wave-
length of 280 nm during the chromatography fraction-
ation process. Reproducibility and efficiency of MARS
column was checked by inspecting the peak position and
height of the flow trough and eluted proteins as well as
Table 4 Most frequent selected peaks in the leave-one-out internal validation (LOO) iterations, with the corresponding
chip surface and mass range
Median m/z value Occurrence* p-value Chip surface Mass range}
Lymph node status
Negative vs Positive
2698.945 15 0.023 IMAC Low
15254.808 14 0.022 IMAC High
3953.177 13 0.024 CM10 Low
Histological subtype
Squamous ca. vs Adenoca.
12802.775 28 0.021 CM10 High
78632.414 11 0.020 IMAC High
Squamous ca. vs Adenosquamous ca.
1532.112 39 0.032 CM10 Low
1532.166 39 0.032 CM10 Low
1627.269 39 0.032 IMAC Low
4783.483 38 0.032 IMAC Low
Adenoca. vs Adenosquamous ca.
1531.463 16 0.012 CM10 Low
LVSI
Negative vs Positive
1741.204 58 0.008 IMAC Low
3224.349 13 0.010 CM10 Low
Recurrence
Negative vs Positive
94029.326 53 0.021 IMAC High
97177.269 52 0.018 IMAC High
78294.986 52 0.027 IMAC High
2044.703 21 0.031 IMAC Low
1979.514 15 0.035 IMAC Low
* The number of times the peak was selected within the different LOO iterations.
} Low mass range: <10 kDa; high mass range >10 kDa.
Abbreviations: CM10 = weak cation exchanger array; IMAC = immobilized metal affinity capture array; ca. = carcinoma; LVSI = lymph vascular space involvement.
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column using pooled serum samples as controls.Concentration and buffer exchange
The collected flow-through fraction containing the low-
abundant proteins was filtered using a 1,000 Da molecu-
lar weight Microsep spin filter (Pall, Zaventem, Belgium)
for the low molecular weight analysis and a 5,000 Da
molecular weight Agilent spin filter (Agilent, Diegem,
Belgium) for the high molecular weight analysis. After a
first filtration step at 7500 × g for 100 and 30 min for
the 1,000 and 5,000 Da spin filter, respectively, a fixed
amount of the SELDI-TOF MS binding buffer (CM10
and IMAC binding buffers: see below for specifications)
was added and the filtration step was repeated. This laststep (adding buffer + filtration) was repeated three times
to perform a buffer exchange from Buffer A to the
SELDI-TOF MS binding buffers. The samples were then
stored at −80°C until further use.Protein profiling with SELDI-TOF MS
Fractions were analysed in duplicate on CM10 (weak cat-
ion exchanger) and copper-coated IMAC30 (immobilized
metal affinity capture) arrays (Bio-Rad, Nazareth, Belgium).
All samples were randomly assigned to the different spots.
For the CM10 arrays, spots were pre-incubated twice with
CM10 binding buffer (0.1 M sodium acetate, pH 4.0) fol-
lowed by application of 100 μl of the sample in the same
binding buffer. For the IMAC30 arrays, spots were pre-
incubated twice with 50 μl of 0.1 M copper sulphate for
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0.1 M sodium acetate buffer pH 4 for 5 min at room
temperature. Spots were then pre-incubated twice with
IMAC30 binding buffer (0.1 M sodium phosphate, 0.5 M
NaCl pH 7) followed by application of 100 μl of the sample
in the same binding buffer. Samples were incubated for
60 min at 4°C with shaking on a MicroMix (Siemens Med-
ical Solutions Diagnostics, Brussels, Belgium). After three
additional wash steps with the same binding buffer and
two final washes with water, 2 × 1 μl of 20% α-cyano-4
-hydroxy cinnamic acid (CHCA) or 100% sinapinic acid
(SPA) (Bio-Rad, Nazareth, Belgium) dissolved in 1% TFA/
100% ACN were applied. CHCA was predominantly used
to improve ionization for lower mass peaks (<10,000 Da)
and SPA for the high mass peaks (10,000–100,000 Da).
Mass analysis was performed using SELDI-TOF MS (PCS
4,000 Enterprise, Ciphergen ProteinChip Reader Inc., Fre-
mont, CA) applying automated data collection protocols
for a molecular weight of <10,000 Da (low molecular
weight protocol) and for 10,000–100,000 Da (high molecu-
lar weight protocol). The following settings were used: (a)
sampling rate 400 MHz; (b) 2 warming shots (not included
in analysis), 10 data shots per point and (c) total number of
points evaluated equal to 12.5% of the spot surface. The
low and high molecular weight protocols were further opti-
mized in pilot studies (data not shown) to reach an optimal
number of peaks and signal to noise (S/N) ratio (the max-
imum number of peaks at S/N> 2 and S/N> 5 were
counted per laser intensity). For the low molecular weight
protocol a laser intensity of 2,500 nJ; focus mass 5,000 Da;
and matrix attenuation 500 Da was chosen. For the low
molecular weight protocol a laser intensity of 2,500 nJ;
focus mass 19,000 Da; and matrix attenuation 5,000 Da
was chosen. Mass accuracy was calibrated externally using
the all-in-one peptide and all-in-one protein standard
according to the manufacturer’s instructions (Bio-Rad) for
the low and high molecular weight analysis, respectively. A
quality control sample (pooled serum) was analyzed weekly
to validate the output of the system. Pooled serum samples
were also used as positive controls (one spot on every chip
was randomly assigned) and run with the same protocol as
the weekly control samples. Data analysis of the control
samples was performed with Shewhart control charts plots
[26]. The fulfillment of the following Westgard rules was
checked: 1:3 s, 2:2 s, 4:1 s, 10×. The analysis of the quality
control samples was within limits during the timeframe
this study. Using the Ciphergen Express Software, baseline
subtraction and noise reduction were completed before
peak intensities were normalized to the total ion current of
the experimental samples. Outlier spectra were identified
and removed from the analyses when the normalisation
factor deviated more than 2 standard deviations. Numeric
data were exported to csv-files for further biostatistical
processing.Data analysis
With the aid of MASDA software the following additional
preprocessing steps were performed [27,28]: (1) peak de-
tection based on changes in the first derivative of a sam-
ple’s intensity curve, (2) peak filtering with exclusion of
peaks below a local noise threshold defined as the median
plus five times the median absolute deviation, and (3) peak
matching/alignment across samples using complete link-
age hierarchical one-dimensional clustering. The signifi-
cance of peaks was determined with the non-parametric
Wilcoxon rank sum test. A p-value of <0.05 was deemed
significant.
Weighted Least Squares Support Vector Machine
(LSSVM) in combination with leave-one-out (LOO) cross-
validation was used to build classifiers [29,30]. For the
optimization of number of peaks included in the classifiers,
the number of peaks tested within each LOO iteration ran-
ged from 1 to maximum 10, only including significant
peaks (p< 0.05). For both CM10 and IMAC30, the low
mass and high mass peaks were simultaneously included in
the models in order of decreasing significance. The optimal
model parameter (regularization parameter of the weighted
LSSVM) was chosen as the one corresponding to the lar-
gest area under the curve (AUC) of the receiver operating
characteristic curve. When multiple parameters with the
same AUC were present, the balanced error rate was mini-
mized with an as high as possible sum of sensitivity and
specificity. The main outcome was LN status (negative vs
positive). Secondary outcomes were histological subtype,
lymph-vascular space involvement (LVSI) and recurrent
disease.
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with corresponding m/z and p-values.
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